February 2026 Research Update

What this month adds

This month, one study makes the brain MRI picture of Krabbe disease feel more organized by showing that different ages of onset tend to cluster into a small number of repeating MRI patterns. [1]

In 27 symptomatic people with Krabbe disease, four MRI patterns were described, and early-infantile and late-infantile cases all fell into the same pattern (pattern 1). Juvenile and adult-onset cases more often showed patterns centered on the back parts of deep white matter (pattern 2) or more isolated involvement of the main movement pathways (corticospinal tracts, pattern 3), with a smaller group showing a patchier pattern that included a cerebellar structure called the dentate hilum (pattern 4). [1]

The same report also describes additional MRI-related measures that might be useful as research markers, such as changes on MR spectroscopy (a scan add-on that can reflect brain chemicals) and diffusion imaging in a small subset. The authors suggest these could potentially help with diagnosis or prognosis, but the study did not track how imaging patterns matched later clinical course. [1]

What it means in everyday terms

For patients and caregivers, this mainly adds a clearer way to describe what doctors may see on MRI at different ages of symptom onset, rather than introducing a new treatment or a new test used in routine care. It may matter most when imaging is being used to support a diagnosis or to help explain why one person with Krabbe disease looks different from another, but it remains uncertain how well these MRI patterns predict what will happen next for an individual. [1]

This work is exploratory because it looked back at existing scans and included only symptomatic people, and genetic information was incomplete for linking patterns to specific variants. Even with those gaps, it helps patients understand that Krabbe disease is not expected to look identical on MRI across all ages, and that repeatable patterns are starting to be mapped in a more structured way. [1]

What this month adds

Two reports this month expand and organize what is known about the GALC gene changes that can cause Krabbe disease, while also reinforcing that symptoms can vary widely, especially in later-onset disease. One report describes two unrelated patients (one with a newly described GALC variant, the other with a known variant), and another combines a single adult case with a broader review to show which variants and symptoms show up often in adult-onset cases. [2] [3]

In two unrelated Iranian patients from consanguineous families, whole-exome sequencing identified one novel homozygous GALC variant (c.836T>G; p.L279X) and one known homozygous variant (c.578T>C; p.I193T), confirmed within families by follow-up testing. The authors described these results as expanding the known set of disease-causing GALC changes and showing clinical heterogeneity. [2]

In an adult-onset case (age 66), the person had spastic paraparesis followed by cognitive decline, with a pathogenic GALC variant (c.857G>A; p.Gly286Asp) and markedly reduced enzyme activity. In the accompanying literature review of 84 adult-onset cases, spasticity was common (58 out of 84), most often as spastic paraplegia (50 out of 84), and most people with available brain MRI data had white matter changes, although a small number had normal MRI. [3]

That same review also highlighted which GALC variants were most frequently reported in adult-onset cases, including c.1901T>C, c.857G>A, and a larger deletion (c.1161+6532_polyA+9kbdel). Taken together with the two-family report, this month reinforces that both common and newly discovered variants continue to be identified, and that genotype and symptoms do not always map in a simple one-to-one way. [3] [2]

What it means in everyday terms

For families, these reports mainly add to the genetic knowledge base that supports diagnosis and family studies, rather than changing treatment options. They also help clarify that later-onset Krabbe disease is often recognized by long-term walking stiffness or leg weakness (spastic paraplegia), and that brain MRI can be abnormal in many adult-onset cases but can occasionally look normal. [3] [2]

What remains uncertain is how reliably any single GALC variant predicts a specific set of symptoms or the pace of change, because the evidence here comes from case reports and a review of published cases with mixed levels of detail. Even so, adding new variants and summarizing the adult-onset spectrum can make future diagnoses more straightforward to confirm and can improve how researchers group patients for studies. [2] [3]

What this month adds

One early study adds support for a treatment idea that aims to reduce harm from psychosine, a toxic fat-like substance that builds up in Krabbe disease. In cells from patients and in a mouse model, 2-hydroxypropyl-alpha-cyclodextrin (HPaCD) bound psychosine and was linked to lower psychosine levels and better nerve myelin measures. [4]

In patient-derived cells, HPaCD reduced psychosine-related cell damage in a dose-dependent way. In a separate experiment using a Krabbe mouse-derived cell line, HPaCD lowered psychosine inside cells after 72 hours. In Twitcher mice (a Krabbe disease model), treatment lowered psychosine in the brain, spinal cord, and sciatic nerve, and was accompanied by measures consistent with better myelination and less scarring-type brain response (astrogliosis). [4]

The mice also showed improvements on movement and activity tests, increased weight gain, and a modest extension in lifespan, and the authors did not observe ototoxicity (hearing-related toxicity) in treated animals. The study frames the main mechanism as psychosine neutralization plus improved clearance, including increased urinary psychosine clearance in treated mice. [4]

What it means in everyday terms

This is laboratory and animal research, so it does not tell us how well HPaCD would work or how safe it would be for people with Krabbe disease. Its main value right now is showing a plausible way to target psychosine directly and measuring multiple signals in mice that moved in a helpful direction, which can guide what future human research might test. [4]

What is still unknown is whether similar psychosine lowering and nervous system effects can be achieved in patients, and what the long-term balance of benefits and risks would be. Even with those uncertainties, this month adds a clearer mechanistic story: a compound can bind psychosine, make it less toxic in cells, and reduce psychosine levels in a whole organism with Krabbe-like disease. [4]